FDA Approval of Eli Lilly Product Zepbound for Obesity
On Wednesday, Nov. 8, 2023, the U.S. FDA approved Eli Lilly (LLY) product ZepboundTM (tirzepatide) injection for the treatment of obesity. Zepbound is the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related . . .